Technical Analysis for JAZZ - Jazz Pharmaceuticals plc

Grade Last Price % Change Price Change
D 123.41 2.08% 2.51
JAZZ closed up 2.08 percent on Monday, March 18, 2024, on 1.39 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup 2.08%
Multiple of Ten Bullish Other 2.08%
Up 3 Days in a Row Strength 2.08%
Oversold Stochastic Weakness 2.08%

   Recent Intraday Alerts

Alert Time
Up 2% about 17 hours ago
Rose Above 20 DMA about 18 hours ago
Rose Above 50 DMA about 18 hours ago
Up 1% about 18 hours ago
60 Minute Opening Range Breakout about 19 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Jazz Pharmaceuticals plc Description

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD, which are orally disintegrating clozapine tablets for the resistant schizophrenia treatment. It also provides Luvox CR to treat obsessive compulsive disorder; Versacloz oral suspension; Caphosol to treat oral mucositis; Quadramet for the treatment of pain in patients whose cancer has spread to the bones; ProstaScint for imaging the extent and spread of prostate cancer; Niravam for the treatment of generalized anxiety and panic disorders; and Parcopa for the symptoms associated with idiopathic Parkinson's disease treatment. In addition, the company offers Collatamp, a surgical implant impregnated with the antibiotic gentamicin; Fomepizole to treat ethylene glycol poisoning; Kidrolase for treating ALL, Leukaemic meningitis, and non-Hodgkin's lymphoma; Xenazine to treat movement disorders associated with Huntington's chorea and hemiballismus; and Custodiol, a ready to use solution used in organ transplantation. Further, it develops Asparec, a pegylated recombinant Erwinia asparaginase that is in Phase I clinical trials for the treatment of patients with ALL with E. coli asparaginase hypersensitivity; and Leukotac, an anti-CD25 monoclonal antibody is in Phase III clinical trials for the treatment of steroid-refractory acute graft vs. host diseases. The company markets its products through its sales representatives, distributors, and wholesalers, as well as through third party vendors. Jazz Pharmaceuticals Public Limited Company is headquartered in Dublin, Ireland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Drugs Pain Imaging Pharmaceutical Products Bone Monoclonal Antibody Lymphoma Prostate Cancer Antibiotics Schizophrenia Chronic Pain Suspension Transplantation Movement Disorders Narcolepsy Host Disease Pharmacokinetics Acute Lymphoblastic Leukemia Obsessive Compulsive Disorder Oral Hygiene Meningitis Organ Transplantation Pegylation Cataplexy Mucositis Organ Transplant Asparaginase Luvox Cr Oral Mucositis Panic Disorder

Is JAZZ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 147.98
52 Week Low 111.2506
Average Volume 606,936
200-Day Moving Average 127.08
50-Day Moving Average 122.40
20-Day Moving Average 122.39
10-Day Moving Average 118.23
Average True Range 3.31
RSI (14) 54.55
ADX 19.17
+DI 30.71
-DI 24.01
Chandelier Exit (Long, 3 ATRs) 124.23
Chandelier Exit (Short, 3 ATRs) 125.39
Upper Bollinger Bands 134.34
Lower Bollinger Band 110.44
Percent B (%b) 0.54
BandWidth 19.53
MACD Line -1.28
MACD Signal Line -1.37
MACD Histogram 0.0903
Fundamentals Value
Market Cap 7.77 Billion
Num Shares 63 Million
EPS 0.83
Price-to-Earnings (P/E) Ratio 148.69
Price-to-Sales 2.05
Price-to-Book 2.23
PEG Ratio 92.30
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 128.67
Resistance 3 (R3) 128.26 126.10 127.80
Resistance 2 (R2) 126.10 124.75 126.30 127.50
Resistance 1 (R1) 124.75 123.93 125.42 125.16 127.21
Pivot Point 122.59 122.59 122.92 122.79 122.59
Support 1 (S1) 121.24 121.25 121.92 121.66 119.61
Support 2 (S2) 119.08 120.42 119.28 119.32
Support 3 (S3) 117.73 119.08 119.02
Support 4 (S4) 118.15